Immune checkpoint inhibitors in advanced non-small cell lung cancer

被引：0
|
作者：
Fabre, Elizabeth [1 ,2 ]
Pecuchet, Nicola [1 ,2 ]
Cadranel, Jacques [3 ,4 ]
机构：
[1] Univ Sorbonne Paris Cite, INSERM UMR S1147, Paris, France
[2] HEGP, AP HP, Med Oncol Serv, Paris, France
[3] Hop Tenon, AP HP, Serv Pneumol, Paris, France
[4] Univ Paris 06, GRC 04 Theranoscan, Paris 6, France
来源：
BULLETIN DU CANCER | 2016年 / 103卷
关键词：
Immunotherapy; Non-small-cell lung cancer; PD-1; PD-L1; PATIENTS PTS; NIVOLUMAB; SAFETY; PEMBROLIZUMAB; ANTI-PD-1; BMS-936558; IPILIMUMAB; ONO-4538; ANTIBODY; THERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T-cell-directed strategies represent currently a major advance in the treatment of advanced non-small- cell lung cancer, regarding their efficacy and tolerance. Nivolumab and pembrolizumab, two monoclonal antibodies targeting programmed cell death protein 1 (PD-1) have shown their efficacy in phase III studies. Several other drugs are developed and the benefit of association is being evaluated. In this article, we propose to summarize the clinical development of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
引用
收藏
页码：S138 / S143
页数：6
相关论文
共 50 条
  • [1] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    [J]. CANCER, 2018, 124 (02) : 248 - 261
  • [2] Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Lin, Gen
    Wang, Zhijie
    Chu, Qian
    Hu, Yi
    Huang, Dingzhi
    Wang, Jun
    Yang, Fan
    Zhong, Wenzhao
    Zhou, Chengzhi
    Zhu, Bo
    Ai, Xinghao
    Cao, Baoshan
    Cao, Yabing
    Chen, Mingqiu
    Chen, Xiaohui
    Chu, Tianqing
    Duan, Jianchun
    Fan, Yun
    Fang, Yong
    Feng, Shuitu
    Feng, Weineng
    Guo, Hui
    Han, Chengbo
    He, Yong
    Hong, Shaodong
    Hu, Jie
    Huang, Meijuan
    Huang, Yan
    Jiang, Da
    Jiang, Kan
    Jiang, Richeng
    Jin, Bo
    Jin, Shi
    Li, Jisheng
    Li, Min
    Li, Ziming
    Li, Chao
    Lin, Jie
    Liu, Anwen
    Liu, Si-Yang Maggie
    Yutao, Liu
    Liu, Zhefeng
    Liu, Zhe
    Liu, Zhenhua
    Liu, Zhentian
    Liu, Zhigang
    Lu, Yuping
    Lv, Tangfeng
    Ma, Zhiyong
    Miao, Qian
    [J]. THORACIC CANCER, 2024, 15 (05) : 419 - 426
  • [3] The role of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Pistamaltzian, Nikolaos F.
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 435 - 447
  • [4] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    [J]. ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [5] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    [J]. ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [6] Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Xue, Chongxiang
    Dong, Huijing
    Chen, Ying
    Lu, Xingyu
    Zheng, Shuyue
    Cui, Huijuan
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (06): : 779 - 788
  • [7] Highlights on immune checkpoint inhibitors in non-small cell lung cancer
    Shen, Meng
    Ren, Xiubao
    [J]. TUMOR BIOLOGY, 2017, 39 (03)
  • [8] Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology
    Manglaviti, Sara
    Brambilla, Marta
    Signorelli, Diego
    Ferrara, Roberto
    Lo Russo, Giuseppe
    Proto, Claudia
    Galli, Giulia
    De Toma, Alessandro
    Occhipinti, Mario
    Viscardi, Giuseppe
    Beninato, Teresa
    Zattarin, Emma
    Bini, Marta
    Lobefaro, Riccardo
    Massa, Giacomo
    Bottiglieri, Achille
    Apollonio, Giulia
    Sottotetti, Elisa
    Di Mauro, Rosa Maria
    Trevisan, Benedetta
    Ganzinelli, Monica
    Fabbri, Alessandra
    de Braud, Filippo G. M.
    Garassino, Marina Chiara
    Prelaj, Arsela
    [J]. CLINICAL LUNG CANCER, 2022, 23 (01) : E17 - E28
  • [9] Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
    Rossi, Emanuela
    Sgambato, Assunta
    De Chiara, Giovanni
    Casaluce, Francesca
    Losanno, Tania
    Sacco, Paola Claudia
    Santabarbara, Giuseppe
    Gridelli, Cesare
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 419 - 428
  • [10] Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer
    Kuo, Chih-Hsi Scott
    Wang, Chin-Chou
    Huang, Yu-Chen
    Pavlidis, Stelios
    Liu, Chien-Ying
    Ko, How-Wen
    Chung, Fu-Tsai
    Lin, Tin-Yu
    Wang, Chih-Liang
    Guo, Yi-Ke
    Yang, Cheng-Ta
    [J]. THORACIC CANCER, 2019, 10 (05) : 1158 - 1166
12345